926 results on '"EVEROLIMUS"'
Search Results
2. Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
3. Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE (COMPOSE)
4. Study of RYZ101 Compared with SOC in Pts W Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy (ACTION-1)
5. Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors
6. Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i. (ADELA)
7. Everolimus and/or Exercise to Prevent Bone Loss in Postmenopausal Women (RapaLoad)
8. A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer (EMBER)
9. Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer
10. Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial
11. Dexamethasone in Reducing Everolimus-Induced Oral Stomatitis in Patients With Cancer (MIST)
12. REgulatory T Cell Therapy to Achieve Immunosuppression REduction (RETIRE)
13. PROMUS PREMIER™ China Post-Approval Study
14. Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation
15. Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer
16. A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)
17. A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment
18. Liver Transplantation With Tregs at MGH (LITTMUS-MGH)
19. Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer
20. European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors (ESMART)
21. DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies
22. Expanding Liver Transplant Immunosuppression Minimization Via Everolimus (ELIMINATE)
23. Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors
24. Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas
25. XIENCE Skypoint Large Vessel Post Approval Study (SPIRIT XLV PAS)
26. Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment
27. A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
28. Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)
29. Expanded Access to Everolimus, for an Individual Patient With Uterine Sarcoma (CTMS#18-0020)
30. Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)
31. Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer (ELEVATE)
32. Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer. (SERENA-1)
33. Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer
34. S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer (e3)
35. A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma
36. Safety and Durability of Sirolimus for Treatment of LAM (MIDAS)
37. Ceritinib and Everolimus in Treating Patients with Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer
38. An Exploratory Study on the Failure of Immunotherapy With Voronib Combined With Everolimus
39. AZD9833 China PK Study (AZD9833)
40. Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0 (BIOMEDE 2)
41. Everolimus Trial in Laryngotracheal Stenosis
42. MTOR Inhibitors in Older Adults
43. Decidua Stroma Cells for Steroid Resistent Acute Graft-versus-host Disease After Allo-HSCT (2017-00355)
44. Comparison of an Ultra-low Strut Thickness Everolimus-eluting Biodegradable Polymer Stent Versus Durable Polymer Everolimus-eluting Stents in Patients Treated with Percutaneous Coronary Intervention (SORT OUT XII)
45. A Study of SIM0270 Combined with Everolimus Vs. Treatment of Physician's Choice in Patients with ER+/HER2- Advanced Breast Cancer (SIMRISE)
46. Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer (AMEERA-1)
47. Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer
48. A Randomized Study of AZD2014 in Combination With Fulvestrant in Metastatic or Advanced Breast Cancer (MANTA)
49. Phase I Study to Evaluate SIM0270 Alone or in Combination in ER+, HER2- Locally Advanced or Metastatic Breast Cancer
50. A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.